Seminars in Hematology
Volume 43, Issue 4 , Pages 207-212 , October 2006

Diffuse Aggressive Histologies of Non-Hodgkin Lymphoma: Treatment and Biology of Limited Disease

References 

  1. Miller TP, Jones SE. Chemotherapy of localized histiocytic lymphoma. Lancet. 1979;8:358–360
  2. Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol. 2004;22:3046–3052
  3. Spier CM, LeBlanc M, Chase EM, Fisher RI, Miller TP. Histologic subtypes do not confer unique outcomes in early-stage lymphoma: Long-term followup of SWOG 8736. Blood. 2004;104:891a;(abstr)
  4. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1989;339:21–26
  5. Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klimo P, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18 year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002;20:197–204
  6. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: Current status. Oncologist. 2003;8:438–447
  7. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (A predictive model for aggressive non-Hodgkin’s lymphoma). N Engl J Med. 1993;329:987–994
  8. Miller TP, LeBlanc M, Spier CM, Chase EM, Fisher RI. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphoma: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood. 2001;98:724a
  9. Miller TP, Unger JM, Spier C, Stea B, Cantu E, LeBlanc M, et al. Effect of adding rituximab to three cycles of CHOP, plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood. 2004;104:48a;(abstr)
  10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235–242
  11. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Blood. 2003;102:29;(abstr)
  12. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197–1205
  13. Fillet G, Bonnet C, Mounier N, Ganem G, Molina T, Thieblement C, et al. No role for chemoradiotherapy when compared with chemotherapy alone in elderly patients with localized low risk aggressive lymphoma: Final results of the LNH93-4 GELA study. Blood. 2005;106:9a;(abstr)
  14. Horning SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, et al. Chemotherapy with or without radiotherapy in limited stage diffuse aggressive non-Hodgkin lymphoma. J Clin Oncol. 2004;22:3032–3038
  15. Riemersma SA, Jordanova ES, Schop RF, Phillipo K, Looujenga LH, Schuuring E, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood. 2000;96:3569–3577
  16. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer. 2001;35:38–48
  17. Jordanova ES, Philippo K, Giphart MJ, Schuuring E, Kluin PM. Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics. 2003;55:203–209
  18. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21:20–27
  19. List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: Relationship to HLA expression and host immunocompetence. Leukemia. 1993;7:398–403
  20. Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004;103:4251–4258
  21. Stopeck AT, Gessner A, Miller TP, Hersh EM, Johnson CS, Cui H, et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res. 2000;6:3904–3909
  22. Jacob MC, Piccinni MP, Bonnefoix T, Sotto MF, Couderc P, Bensa JC, et al. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin’s lymphoma: Reactivity toward the malignant clone. Blood. 1990;75:1154–1162
  23. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785
  24. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  25. Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, Willemze R, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671–3678
  26. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947
  27. Jaffe ES. WHO Classification of Tumours, Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001;
  28. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–862
  29. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–3879

PII: S0037-1963(06)00149-1

doi: 10.1053/j.seminhematol.2006.07.001

Seminars in Hematology
Volume 43, Issue 4 , Pages 207-212 , October 2006

Article Tools